| Literature DB >> 20304037 |
Matteo Martini1, Maria Grazia Testi, Matteo Pasetto, Maria Cristina Picchio, Giulio Innamorati, Marta Mazzocco, Stefano Ugel, Sara Cingarlini, Vincenzo Bronte, Paola Zanovello, Mauro Krampera, Federico Mosna, Tiziana Cestari, Anna Pia Riviera, Nadia Brutti, Ottavia Barbieri, Lina Matera, Giuseppe Tridente, Marco Colombatti, Silvia Sartoris.
Abstract
De novo expression of B7-1 impaired tumorigenicity of TRAMP-C2 mouse prostate adenocarcinoma (TRAMP-C2/B7), but it did not elicit a protective response against TRAMP-C2 parental tumor, unless after in vitro treatment with IFN-gamma. TRAMP-C2 cells secrete TGF-beta and show low MHC-I expression. Treatment with IFN-gamma increased MHC-I expression by induction of some APM components and antagonizing the immunosuppressant activity of TGF-beta. Thus, immunization with TRAMP-C2/B7 conferred protection against TRAMP-C2-derived tumors in function of the IFN-gamma-mediated fine-tuned modulation of either APM expression or TGF-beta signaling. To explore possible clinical translation, we delivered IFN-gamma to TRAMP-C2 tumor site by means of genetically engineered MSCs secreting IFN-gamma. (c) 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20304037 DOI： 10.1016/j.vaccine.2010.03.007
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641